| Literature DB >> 24134426 |
Salimah H Meghani1, Jesse Chittams, Alexandra L Hanlon, Joseph Curry.
Abstract
BACKGROUND: Conjoint Analysis (CA) can serve as an important tool to study health disparities and unique factors underlying decision-making in diverse subgroups. However, methodological advancements are needed in exploiting this application of CA. We compared the internal and external predictive validity and inter-temporal stability of Choice-based-Conjoint (CBC) analysis between African-Americans and Whites in the clinical context of preferences for analgesic treatment for cancer pain.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24134426 PMCID: PMC3924351 DOI: 10.1186/1472-6947-13-118
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Demographic characteristics of study participants by race (N = 241)
| Age | 53.7 (11.0) | 52.7 (10.1) | 54.5 (11.6) | .194 |
| Heath literacy score | 13.0 (2.6) | 13.0 (3.0) | 13.0 (2.4) | .934 |
| Comfort with computers | 3.3 (1.4) | 3.1 (1.4) | 3.5 (1.4) | .033 |
| | | | | |
| Gender | | | | .019 |
| Male | 111 (46) | 38 (37) | 73 (53) | |
| Female | 130 (54) | 64 (63) | 66 (47) | |
| Marital status | | | | <.001 |
| Married | 133 (55) | 33(32) | 100 (72) | |
| Separated/ divorced/widowed | 62 (26) | 42 (41) | 20 (14) | |
| Never married | 46 (19) | 27(27) | 19 (14) | |
| Education | | | | .011 |
| Elementary | 3 (1) | 2 (2) | 1 (2) | |
| High school | 84 (35) | 42 (41) | 42 (42) | |
| College/trade school | 117 (49) | 51 (50) | 66 (51) | |
| More than college | 37 (15) | 7 (7) | 30 (7) | |
| Income | | | | <.001 |
| < 30, 000 | 85 (35) | 57 (56) | 28 (20) | |
| 30-50,000 | 44 (18) | 26 (25) | 18 (13) | |
| 50-70,000 | 41 (17) | 13 (13) | 28 (20) | |
| 70-90,000 | 25 (11) | 3 (3) | 22 (16) | |
| >90,000 | 46 (19) | 3 (3) | 43 (31) | |
| Health insurance | | | | <.001 |
| Private | 123 (51) | 30 (29) | 93 (67) | |
| Medicaid | 33 (14) | 28 (27) | 5 (4) | |
| Medicare | 50 (21) | 25 (25) | 25 (18) | |
| Multiple | 26 (11) | 13 (13) | 13 (9) | |
| Other | 8 (3) | 6 (6) | 2 (1) | |
| Cancer type | | | | .895 |
| Lung | 39 (16) | 14 (14) | 25 (18) | |
| Breast | 40 (17) | 19 (19) | 21 (15) | |
| GI | 41 (17) | 15 (15) | 26 (19) | |
| GU/reproductive | 28 (11) | 12 (12) | 16 (11) | |
| Multiple myeloma | 36 (15) | 17 (16) | 19 (14) | |
| Other solid tumors | 57 (24) | 25 (24) | 32 (23) |
†p-values are based on t-tests for continuous variables and chi-squared for categorical variables.
Aggregate results of analgesic treatment utilities over-time estimated using CBC
| | | ||||
|---|---|---|---|---|---|
| | | | |||
| | < 50% | | −90.3 | | −91.8 |
| | 60−70% | | −12.9 | | −13.8 |
| | 80−90% | | 30.9 | | 36.9 |
| | 100% | | 72.3 | | 68.7 |
| | | | |||
| | Confusion | | −37.8 | | −23.4 |
| | Drowsiness/Dizziness | | 23.8 | | 12.0 |
| | Heartburn/Sour Stomach | | 13.7 | | 9.2 |
| | Constipation | | 16.9 | | 19.1 |
| | Nausea/Vomiting | | −16.7 | | −16.9 |
| | | | |||
| | Mild | | 32.5 | | 34.1 |
| | Moderate | | 24.1 | | 17.6 |
| | Severe | | −56.6 | | −51.7 |
| | | | |||
| | Oxycontin or Morphine-like | | 19.5 | | 19.2 |
| | Motrin or Aleve-like | | −19.5 | | −19.2 |
| | | | |||
| | $10−$20 | | 24.5 | | 28.7 |
| | $30−$40 | | 20.8 | | 18.3 |
| | $50−$60 | | −0.16 | | 6.5 |
| | $70−$90 | | −11.9 | | −6.4 |
| $100 or more | −33.1 | −47.1 | |||
*The attributes were identified based on pilot work with African Americans and Whites with cancer pain. ‡Relative importance scores sum to 100 across all attributes; †Aggregate utilities associated with each level of the attribute; smaller or more negative preference weight indicates less preference for that level of an attribute.
Aggregate utilities of analgesic treatment for cancer pain "by race" over-time
| | ||||||
|---|---|---|---|---|---|---|
| < 50% | −102.5 | −73.8 | .000 | −101.7 | −78.8 | .006 |
| 60-70% | −15.7 | −9.12 | .002 | −15.2 | −11.9 | .337 |
| 80-90% | 37.1 | 22.6 | .000 | 40.4 | 32.3 | .062 |
| 100% | 81.1 | 60.3 | .000 | 76.5 | 58.5 | .007 |
| Confusion | −32.1 | −45.5 | .081 | −11.7 | −38.8 | .000 |
| Drowsiness/dizziness | 21.0 | 27.6 | .145 | 12.8 | 11.1 | .717 |
| Heartburn/sour stomach | 13.3 | 14.4 | .865 | 7.8 | 11.0 | .518 |
| Constipation | 18.9 | 14.2 | .448 | 13.5 | 26.5 | .047 |
| Nausea/vomiting | −21.1 | −10.7 | .056 | −22.4 | −9.8 | .048 |
| Mild | 33.0 | 31.8 | .636 | 38.2 | 28.7 | .022 |
| Moderate | 26.7 | 20.6 | .010 | 18.7 | 16.1 | .212 |
| Severe | −59.7 | −52.3 | .112 | −56.9 | −44.8 | .034 |
| .176 | ||||||
| Oxycontin or morphine-like pain medicine | 19.9 | 19.0 | .904 | 23.4 | 13.8 | .272 |
| Motrin or aleve-like pain medicine | −19.9 | −19.0 | .904 | −23.4 | −13.8 | .272 |
| .355 | ||||||
| $10-$20 | 25.0 | 23.8 | .608 | 24.7 | 33.9 | .003 |
| $30-$40 | 22.0 | 19.1 | .122 | 16.1 | 21.2 | .019 |
| $50-$60 | -.11 | -.23 | .889 | 7.9 | 4.6 | .023 |
| $70-$90 | −12.3 | −11.5 | .598 | −5.9 | −7.1 | .466 |
| $100 or more | −34.6 | −31.1 | .232 | −42.8 | −52.7 | .037 |
†Aggregate utilities associated with each level of the attribute; smaller or more negative preference weight indicates less preference for that level of an attribute.
‡Relative importance scores sum to 100 across all attributes. P-values are based on 2-tailed two sample t-test.
Internal and external predictive validity of CBC utilities by race over-time
| | ||||||
|---|---|---|---|---|---|---|
| 0.789 | 0.767−0.812 | 0.826 | 0.804−0.848 | 3.04% | 8.04% | |
| 0.849 | 0.835−0.863 | 0.846 | 0.828−0.865 | 4.20% | 10.24% | |
†RLH = Root Liklihood; ‡MAE = Mean Absolute Error.
Inter-temporal stability of CBC utilities over-time
| | |||||||
|---|---|---|---|---|---|---|---|
| 0.88/0.40 | 0.17 (0.08, 0.25) | 4.6 (1.9, 11.6) | 0.62/0.46 | 0.04 (−0.10, 0.17) | 0.97/0.34 | 0.22 (0.12, 0.33) | |
| 0.78/0.59 | 0.13 (0.04, 0.22) | 5.0 (1.6, 15.9) | 0.86/0.58 | 0.24 (0.08, 0.39) | 0.50/0.60 | 0.02 (−0.07, 0.10) | |
| 0.71/0.80 | 0.32 (0.17, 0.46) | 10.0 (3.6, 27.6) | 0.80/0.77 | 0.33 (0.13, 0.54) | 0.64/0.83 | 0.29 (0.08, 0.51) | |
*Dominant Utility is defined as a relative importance ranking of an attribute at T1 (baseline) of at least 50%.
Sensitivity is defined as the proportion of participants who ranked the same attribute high (either 1st or 2nd) at T2 (3-months) as the dominant attribute at Time 1; Specificity is defined as the proportion of participants who did not rank the given attribute high (either 1st or 2nd) at T2 of those who did not rank the given utility as dominant at T1.
The odds of the given utility to be ranked high (either 1st or 2nd) at T2 if it is the dominant utility at T1.
Note: Very few participants had strong preferences associated with “out-of-pocket cost” and “severity of side-effects”, thus there was not enough data to evaluate the Inter-temporal stability of those preferences.